Notice of Results and Investor Presentation

22 September 2025

Physiomics plc

("Physiomics" or the "Company")

Notice of Results and Investor Presentation via Investor Meet Company

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that the Company will be releasing its audited results for the year ended 30 June 2025, on 29 September 2025.

The Company further announces that following the merger of its previous auditor, Shipleys LLP, with Moore Kingston Smith LLP ("MKS") and the subsequent rebranding effective May 2025, MKS will serve as Physiomics' auditors on an ongoing basis.

Dr Peter Sargent (CEO) and Dr Jim Millen (Non-Executive Chairman) will provide a live presentation relating to the full year results and wider business update via Investor Meet Company on 1 October 2025 at 12:00 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted before the event via the Investor Meet Company dashboard up until 30 September 2025, 09:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet PHYSIOMICS PLC via:

https://www.investormeetcompany.com/physiomics-plc/register-investor

Investors who already follow PHYSIOMICS PLC on the Investor Meet Company platform will automatically be invited.

For more information about Physiomics and its services, please visit www.physiomics.co.uk.  

Enquiries: 

Physiomics plc  

Dr Peter Sargent, CEO  

+44 (0)1235 841575 

Hybridan LLP (Broker) 

Claire Louise Noyce 

+44 (0) 203 764 2341 

Strand Hanson Ltd (NOMAD) 

James Dance & James Bellman 

+44 (0)20 7409 3494 

Notes to Editor 

About Physiomics 

Physiomics plc combines expertise across Modelling & Simulation, Biometrics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.